FDA approves treatments for irritable bowel syndrome
On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult men and women. Read…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.